Literature DB >> 30377253

Soluble Siglec-14 glycan-recognition protein is generated by alternative splicing and suppresses myeloid inflammatory responses.

Po-Chun Jimmy Huang1,2, Penk-Yeir Low1, Iren Wang1, Shang-Te Danny Hsu1,2, Takashi Angata3,2.   

Abstract

Human sialic acid-binding immunoglobulin-like lectin 14 (Siglec-14) is a glycan-recognition protein that is expressed on myeloid cells, recognizes bacterial pathogens, and elicits pro-inflammatory responses. Although Siglec-14 is a transmembrane protein, a soluble form of Siglec-14 is also present in human blood. However, the mechanism that generates soluble Siglec-14 and what role this protein form may play remain unknown. Here, investigating the generation and function of soluble Siglec-14, we found that soluble Siglec-14 is derived from an alternatively spliced mRNA that retains intron 5, containing a termination codon and thus preventing the translation of exon 6, which encodes Siglec-14's transmembrane domain. We also note that the translated segment in intron 5 encodes a unique C-terminal 7-amino acid extension, which allowed the specific antibody-mediated detection of this isoform in human blood. Moreover, soluble Siglec-14 dose-dependently suppressed pro-inflammatory responses of myeloid cells that expressed membrane-bound Siglec-14, likely by interfering with the interaction between membrane-bound Siglec-14 and Toll-like receptor 2 on the cell surface. We also found that intron 5 contains a G-rich segment that assumes an RNA tertiary structure called a G-quadruplex, which may regulate the efficiency of intron 5 splicing. Taken together, we propose that soluble Siglec-14 suppresses pro-inflammatory responses triggered by membrane-bound Siglec-14.
© 2018 Huang et al.

Entities:  

Keywords:  G-quadruplex; Siglec; alternative splicing; biomarker; inflammation; sialic acid; soluble receptor; toll-like receptor (TLR); transmembrane signaling

Mesh:

Substances:

Year:  2018        PMID: 30377253      PMCID: PMC6314137          DOI: 10.1074/jbc.RA118.005676

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Detection of anti-Siglec-14 alloantibodies in blood components implicated in nonhaemolytic transfusion reactions.

Authors:  Kazuta Yasui; Takashi Angata; Nobuki Matsuyama; Rika A Furuta; Takafumi Kimura; Hitoshi Okazaki; Yoshihiko Tani; Susumu Nakano; Hisashi Narimatsu; Fumiya Hirayama
Journal:  Br J Haematol       Date:  2011-04-08       Impact factor: 6.998

2.  The MaxQuant computational platform for mass spectrometry-based shotgun proteomics.

Authors:  Stefka Tyanova; Tikira Temu; Juergen Cox
Journal:  Nat Protoc       Date:  2016-10-27       Impact factor: 13.491

Review 3.  Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.

Authors:  Takashi Angata; Corwin M Nycholat; Matthew S Macauley
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

Review 4.  Siglecs and immune regulation.

Authors:  Shiv Pillai; Ilka Arun Netravali; Annaiah Cariappa; Hamid Mattoo
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

5.  Quaking I controls a unique cytoplasmic pathway that regulates alternative splicing of myelin-associated glycoprotein.

Authors:  Lixia Zhao; Mariana D Mandler; Hong Yi; Yue Feng
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

6.  Bronchopulmonary Dysplasia: Executive Summary of a Workshop.

Authors:  Rosemary D Higgins; Alan H Jobe; Marion Koso-Thomas; Eduardo Bancalari; Rose M Viscardi; Tina V Hartert; Rita M Ryan; Suhas G Kallapur; Robin H Steinhorn; Girija G Konduri; Stephanie D Davis; Bernard Thebaud; Ronald I Clyman; Joseph M Collaco; Camilia R Martin; Jason C Woods; Neil N Finer; Tonse N K Raju
Journal:  J Pediatr       Date:  2018-03-16       Impact factor: 4.406

7.  Deletion polymorphism of SIGLEC14 and its functional implications.

Authors:  Masahiro Yamanaka; Yukinari Kato; Takashi Angata; Hisashi Narimatsu
Journal:  Glycobiology       Date:  2009-04-15       Impact factor: 4.313

8.  Factors secreted from dental pulp stem cells show multifaceted benefits for treating experimental rheumatoid arthritis.

Authors:  Jun Ishikawa; Nobunori Takahashi; Takuya Matsumoto; Yutaka Yoshioka; Noriyuki Yamamoto; Masaya Nishikawa; Hideharu Hibi; Naoki Ishigro; Minoru Ueda; Koichi Furukawa; Akihito Yamamoto
Journal:  Bone       Date:  2015-11-19       Impact factor: 4.398

9.  An RNA G-quadruplex in the 5' UTR of the NRAS proto-oncogene modulates translation.

Authors:  Sunita Kumari; Anthony Bugaut; Julian L Huppert; Shankar Balasubramanian
Journal:  Nat Chem Biol       Date:  2007-02-25       Impact factor: 15.040

10.  Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus.

Authors:  Syed Raza Ali; Jerry J Fong; Aaron F Carlin; Tamara D Busch; Rebecka Linden; Takashi Angata; Thomas Areschoug; Mana Parast; Nissi Varki; Jeffrey Murray; Victor Nizet; Ajit Varki
Journal:  J Exp Med       Date:  2014-05-05       Impact factor: 14.307

View more
  3 in total

1.  Siglec-14 Enhances NLRP3-Inflammasome Activation in Macrophages.

Authors:  Chih-Ming Tsai; Angelica M Riestra; Syed Raza Ali; Jerry J Fong; Janet Z Liu; Gillian Hughes; Ajit Varki; Victor Nizet
Journal:  J Innate Immun       Date:  2019-12-05       Impact factor: 7.349

2.  Tumor Derived SIGLEC Family Genes May Play Roles in Tumor Genesis, Progression, and Immune Microenvironment Regulation.

Authors:  Zheng Chen; Mincheng Yu; Lei Guo; Bo Zhang; Shuang Liu; Wentao Zhang; Binghai Zhou; Jiuliang Yan; Qianni Ma; Zhangfu Yang; Yongsheng Xiao; Yongfeng Xu; Hui Li; Qinghai Ye
Journal:  Front Oncol       Date:  2020-11-09       Impact factor: 6.244

Review 3.  Shaping the Innate Immune Response Through Post-Transcriptional Regulation of Gene Expression Mediated by RNA-Binding Proteins.

Authors:  Anissa Guillemin; Anuj Kumar; Mélanie Wencker; Emiliano P Ricci
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.